Previous Close | $2.91 |
AI Value | $116.69 |
Upside potential | +3,910% |
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on developing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for complicated urinary tract infections (cUTI) and acute pyelonephritis (AP) caused by certain bacteria. Spero's pipeline also includes SPR720, a novel oral antibiotic targeting pulmonary non-tuberculous mycobacterial (NTM) infections, and SPR206, a next-generation polymyxin antibiotic for MDR Gram-negative infections. The company operates in a highly competitive and regulated market, with its primary competitive advantage being its focus on addressing unmet medical needs in antibiotic resistance, a growing global health concern.
Focus on novel antibiotics targeting resistant infections; tebipenem HBr has potential to be first oral carbapenem antibiotic for cUTI/AP.
Spero Therapeutics presents a high-risk, high-reward investment opportunity given its focus on the critical but challenging antibiotic market. The company's lead candidate, tebipenem HBr, addresses a significant unmet need, but regulatory and commercial risks remain substantial. Investors should closely monitor clinical trial progress, funding runway, and potential partnership announcements. The stock is suitable only for those with high risk tolerance and a long-term perspective.
Spero Therapeutics 10-K filings, investor presentations, company website, clinicaltrials.gov, CARB-X press releases.
Historical valuation data is not available at this time.